Method for diagnosing multiple sclerosis
AssigneeGlycominds Ltd.
InventorsNir Dotan, Avinoam Dukler
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.
Claims43
A method of identifying a subject with a first Neurological Event (FNE) who is likely to progress to relapse remitting multiple sclerosis (RRMS), the method comprising
- providing a test sample from a subject with a FNE;
- detecting in said test sample at least one antibody selected from the group consisting of an anti-Glc(α1,4)Glc(α) (GAGA4) antibody and an anti-Glc(α1,6)Glc(α) (GAGA6) antibody;
- and
- comparing the levels of said antibody in said test sample to a control sample whose RRMS status is known,
- thereby identifying a FNE subject likely to progress to RRMS.
A method of identifying a subject with a First Neurological Event (FNE) who is likely to progress to relapse remitting multiple sclerosis (RRMS), the method comprising
- providing a serum sample from a subject with a FNE;
- detecting in said test sample at an anti-Glc(α1,4)Glc(α) (GAGA4) IgM antibody and an anti-Glc(α1,6)Glc(α) (GAGA6) IgM antibody;
- and
- comparing the levels of said antibodies in said test sample to a control sample known not to have RRMS,
- wherein an elevated level of said antibodies in said test sample as compared to said control sample indicates said FNE subject is likely to progress to RRMS.
A method of identifying a subject with RMMS who has active multiple sclerosis disease, the method comprising
- providing a test sample from a subject with RMMS;
- detecting in said test sample at least one antibody selected from the group consisting of an anti-Glc(α1,4)Glc(α) antibody and an anti-α-GlcNAc (GNa) antibody;
- and
- comparing the levels of said antibody in said test sample to a control sample whose relapsing status is known,
- thereby identifying an RRMS subject likely to have active multiple sclerosis disease.
A method of identifying a subject with RRMS who has active multiple sclerosis disease, the method comprising
- providing a test sample from a subject with RRMS;
- detecting in said test sample an anti-Glc(α1,4)Glc(α) IgM antibody and an anti-α-GlcNAc (GNa) IgM antibody;
- and
- comparing the levels of said antibodies in said test sample to a control sample obtained from a patient or patients whose relapsing status is known,
- wherein an elevated level of said antibodies in said test sample as compared to said control sample indicates said subject has active multiple sclerosis.
A purified composition comprising a glycan-containing molecule, wherein said glycan-containing molecule is selected from the group consisting of
- a Glc(α1,2)Glc(α)-containing glycan,
- a Glc(α1,3)Glc(α)-containing glycan,
- a Glc(α1,6)Glc(α)-containing glycan, and
- a α-GlcNAc-containing glycan.
Dependencies are inferred from the claim text.